Written by The global biologics contract manufacturing market is undergoing significant expansion as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing activities to specialized contract manufacturing organizations (CMOs). Growing biologics pipelines, rising demand for monoclonal antibodies and recombinant proteins, and the increasing complexity of biologic production are encouraging drug developers to seek external manufacturing expertise. The COVID-19 pandemic further highlighted the strategic importance of flexible manufacturing capacity, particularly for vaccines and other biologic therapies. RNA-based vaccine development created additional opportunities for contract manufacturers with capabilities in process development, analytical testing, scale-up, formulation, and commercial production.
👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78042
Market Size and Growth
According to the supplied Transparency Market Research figures, the global biologics contract manufacturing market was valued at US$13.3 billion in 2020 and is projected to expand at a 12.2% CAGR from 2021 to 2031, surpassing US$47.3 billion by 2031. Growth is supported by increasing biopharmaceutical sales, a broad clinical pipeline, greater R&D investment, and outsourcing among emerging biotechnology companies. Small and virtual biotech firms, in particular, often lack extensive internal manufacturing infrastructure, creating sustained demand for specialized external production partners.
Market Segmentation
The market can be analyzed across service type, product type, source, and geography. Product demand includes monoclonal antibodies, recombinant proteins, vaccines, and other biologic products, while services span development, process optimization, analytical services, clinical manufacturing, and commercial-scale production. Monoclonal antibodies remain an important opportunity because of their application across oncology, autoimmune diseases, and other chronic conditions. Vaccine manufacturing has also become strategically significant as companies seek scalable platforms capable of responding rapidly to infectious-disease outbreaks and changing healthcare requirements.
Regional Analysis
North America represents a major market for biologics contract manufacturing because of its established biopharmaceutical industry, strong R&D ecosystem, and high concentration of biotechnology companies. Europe also remains an important manufacturing and research hub, supported by advanced pharmaceutical infrastructure and regulatory capabilities. Asia-Pacific is attracting increasing attention as companies seek cost-efficient production, additional manufacturing capacity, and access to specialized biotechnology expertise. Countries such as South Korea and China have strengthened their positions through investments in large-scale biologics manufacturing facilities and technology platforms.
Competitive Landscape
The competitive environment is fragmented, with established multinational manufacturers competing alongside specialized regional providers. Key companies identified in the supplied market material include Lonza Group, Samsung Biologics, Patheon by Thermo Fisher Scientific, Cambrex Corporation, Siegfried Holding, Fujifilm, AbbVie, Boehringer Ingelheim, Recipharm, WuXi Biologics, and Catalent. Strategic collaborations, capacity expansion, technology investments, and long-term manufacturing agreements remain important competitive strategies. Partnerships supporting products such as ublituximab demonstrate how contract manufacturing relationships can help pharmaceutical companies secure capacity for commercialization.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:Â
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453